哪位大侠能帮我把这段话，翻译成中文呢，重重谢!!!

suixin12345

Targeted therapies that deliver the expected anti-tumor
1 m# U6 y7 e+ Y* x) W5 Eeffects while mitigating the adverse effects are taking2 \8 _" a6 U& m0 D
the cancer world by storm. The need for such therapies
; z2 |* {8 n3 s% din non-small cell lung cancer (NSCLC), where systemic
4 {# @" @. ?  P1 V8 gcytotoxic chemotherapies still remain the backbone of3 ?8 \; i3 p2 C# u/ N' C/ K
management, is felt more than ever before. Runway
; B. i/ u. m5 }; a  Isuccess of immunotherapies such as Ipilimumab for' f3 Z2 b' \$ P5 P- j) v6 {
melanoma has brought excitement among oncologists.
; m6 A- L0 t: D) `( nImmune-based treatments are in various stages of5 m) v' D6 [5 W
evaluation for NSCLC as well. Immunotherapies using
3 m' A* e+ @/ f) j+ ^strategies of antigen based or cell based vaccines, and
7 c+ w. a* x: N* ~, ?  Sblocking immune checkpoints are of substantial interest.
, [# h2 P8 D# Q4 g: X# E$ P3 ]4 X0 }Meaningful clinical responses are yet to be reaped
7 {0 R7 t8 f. }$ T- a9 ?1 h/ e% afrom these new treatment modalities.
3 \. d1 n8 q" I" c+ w) @% ~3 C  z, q. R& C9 g

  U3 z0 U5 F" U9 t* x+ Z  @Lung cancer is the leading cause of cancerdeath
4 i5 W3 B) v( `& N7 S* @' T% sworldwide. Majority of these patients have nonsmall
  H  B/ h1 q9 N- a2 p. s) g9 Qcell lung cancer (NSCLC). Traditional chemotherapy& a" V! \2 N% v8 u$ s
is limited by its high toxicity. Emerging data have; o/ {; `# v( C. o& E! s
demonstrated promising outcome of immunotherapy in
3 k0 y& Q  s- m8 RNSCLC. This review delineated the rationale and potential$ Y) o4 N* P! H
targets of cancer immunotherapy, with a summary
% P, h6 k0 J  c  d2 R# Uof immunotherapeutic agents for treatment of NSCLC.$ E5 A+ `8 k0 N# U
Protein/peptide-based and cell-based vaccines, as well# i# I; S' c: S5 R* b" o% p% {$ _
as immune checkpoint targeted agents such as Ipilimumab8 ?" S3 n& s. ~
and PD-1 pathway inhibitors were discussed. In
7 C# R, V7 ~) y3 t" @addition, we reviewed ongoing immunotherapy-based; j0 J7 H5 D+ m7 {* O
studies including several major phase Ⅱ/Ⅲ clinical trials,0 l8 ^0 K! J7 A3 x/ o# D7 o
results of which will be available soon for incorporation* g8 }' Z8 y7 c
into clinical practice.

suixin12345

多谢，感激

zljbionero

靶向治疗正快速的成为治疗癌症的有效方法，靶向治疗可以在传递抗癌效果的同时减少副作用的产生。非小细胞肺癌治疗市场对于这种治疗方法的需求达到了前所有的程度，现今非小细胞肺癌的治疗方法还是以化疗为主。免疫治疗在治疗癌症方面的成功，例如治疗黑色素瘤的伊匹单抗药物，给癌症专家们带来了巨大的惊喜。以免疫为基础的治疗方法在治疗非小细胞肺癌方面也正处于不同的临床评估阶段。免疫治疗对科学家来说非常具有吸引力，它主要通过以抗原或细胞为主要成分的疫苗来阻断免疫的检验点。但这种崭新治疗方法的流行还需要更多临床治疗方案的支持。1 _. G% P- A" _! |
肺癌是全世界致死率最高的癌症。而这其中绝大多数为非小细胞肺癌。传统的化疗方法因为它的高毒性副作用而受到限制。现在越来越多的数据显示了免疫治疗在治疗非小细胞肺癌方面的光明前景。本篇综述介绍了癌症免疫治疗的基本原理和癌症治疗的潜在靶点，还汇总了现今治疗非小细胞肺癌的免疫治疗试剂。文中介绍了成分为蛋白质/多肽和细胞的疫苗，阻断免疫检验点的伊匹单抗，PD-1通路抑制剂。我们最后还介绍了正在进行的几个重要的免疫治疗的二期三期临床试验，这些试验的结果很可能将应用到临床治疗当中。